CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
CBD-Based Drug Reduces Pericarditis Pain And Inflammation, Shows New Clinical Study
基於CBD的藥物減輕心包炎疼痛和炎症，顯示新的臨床研究
Cardiol Therapeutics Inc. (NASDAQ:CRDL), a clinical-stage life sciences company, reported results from its Phase II open-label MAvERIC-Pilot study of CardiolRx, a cannabidiol-based therapy for treating symptomatic recurrent pericarditis. Cannabidiol (CBD) is a non-psychoactive compound found in the cannabis plant.
Cardiol Therapeutics Inc.（納斯達克：CRDL）是一家臨床階段的生命科學公司，報告了其對CardiolRx的第二階段開放標籤MAvERIC-Pilot研究的結果，這是一種用於治療症狀性反覆心包炎的基於大麻二酚的治療方法。大麻二酚（CBD）是一種在大麻植物中發現的非精神活性化合物。
The study, presented at the American Heart Association Scientific Sessions 2024, showed sustained reductions in pericarditis pain and inflammation over 26 weeks.
這項研究在美國心臟協會科學會議2024上發佈，顯示在26周內心包炎的疼痛和炎症持續減少。
"The data reported today show that patients enrolled in MAvERIC-Pilot, despite the severity of their disease, experienced clinically relevant and rapid reductions in both their pericarditis pain and C-reactive protein levels that were...
「今天報告的數據表明，儘管疾病嚴重，參與MAvERIC-Pilot的患...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間